Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Sclerosis, Scleroderma Clear all

Conditions: Systemic Sclerosis
Interventions: Cyclophosphamide, Mesna, G-CSF, Leukopheresis, Total Body Irradiation; Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Morphea, Localized Scleroderma
Interventions: topical calcipotriene 0.005% ointment; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Raynaud's Disease
Interventions: Pletal; Drug
Lead sponsor: Otsuka America Pharmaceutical; Industry
Eligibility: 5 Years to 16 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 19
States / cities: Anchorage, Alaska • Fresno, California • Madera, California + 16 more

Conditions: Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions: Resource sheets, Community Resource Specialist, Nurse Navigator; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Scleroderma, Raynaud's Syndrome
Interventions: Onabotulinumtoxin A, sterile saline solution; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
Interventions: Treatment Protocol, Standard of Care; Other
Lead sponsor: Canadian Scleroderma Research Group; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: SYSTEMIC SCLERODERMA
Interventions: standard of care, stem cell transplantation; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: Up to 60 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD0120, SOC; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 8 more

Conditions: Fibrosis Lung, Systemic Sclerosis
Interventions: Bronchoscopy with lavage; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Hypertension, Systemic Sclerosis, Mixed Connective Tissue Disease, Heart Failure With Normal Ejection Fraction, Healthy
Interventions: No intervention. Biospecimen collection only; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
Interventions: UVA-1 Phototherapy, Placebo; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions: Ophthalmic Emulsion; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more

Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions: Specimen sample; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: JBT-101, Placebo, Part B Open-Label Extension; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more

Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions: Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more

Conditions: Systemic Sclerosis
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Scleroderma
Interventions: LCI testing; Diagnostic Test
Lead sponsor: National Jewish Health; Other
Eligibility: 21 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Scars, Scleroderma
Interventions: Laser Treatment; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Scleroderma, Systemic Sclerosis
Interventions: Registry; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Scleroderma, Ssc
Interventions: Occupational therapy treatment; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana • Baltimore, Maryland

Conditions: Systemic Sclerosis
Interventions: SAR156597, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more

Search by objective public record fields.

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

Molecular Effects of Topical Calcipotriene on Morphea

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

The Small Intestine Bacterial Overgrowth Study Pilot

Rheumatology Patient Registry and Biorepository

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

A Study of AZD0120 in Autoimmune Diseases

Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD

New Orleans Pulmonary Hypertension Biobank

Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis

Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD

Laser Treatment for the Improvement of Scars and Scleroderma

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Duke Scleroderma Clinic Patient Registry

Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis